Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Down 50.9% in February

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large drop in short interest in February. As of February 28th, there was short interest totalling 1,080,000 shares, a drop of 50.9% from the February 13th total of 2,200,000 shares. Based on an average daily volume of 5,220,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 8.4% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Moleculin Biotech in a report on Monday, March 3rd. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Finally, StockNews.com assumed coverage on Moleculin Biotech in a report on Thursday. They set a “sell” rating on the stock.

Moleculin Biotech Trading Down 2.6 %

Shares of NASDAQ MBRX traded down $0.03 during mid-day trading on Friday, hitting $1.13. 492,587 shares of the stock traded hands, compared to its average volume of 6,934,791. Moleculin Biotech has a twelve month low of $0.40 and a twelve month high of $8.85. The firm has a 50 day simple moving average of $1.42 and a two-hundred day simple moving average of $2.07.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.